De Toni EN - Search Results

1

Immune checkpoint inhibitors: use them early, combined and instead of TACE?

De Toni EN. De Toni EN. Gut. 2020 Oct;69(10):1887-1888. doi: 10.1136/gutjnl-2019-319658. Epub 2019 Oct 14. Gut. 2020. PMID: 31611301 Free PMC article. No abstract available.

2

The role of the novel Th17 cytokine IL-26 in intestinal inflammation.

Dambacher J, Beigel F, Zitzmann K, De Toni EN, Göke B, Diepolder HM, Auernhammer CJ, Brand S. Dambacher J, et al. Among authors: de toni en. Gut. 2009 Sep;58(9):1207-17. doi: 10.1136/gut.2007.130112. Epub 2008 May 15. Gut. 2009. PMID: 18483078

3

JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand.

Mucha SR, Rizzani A, Gerbes AL, Camaj P, Thasler WE, Bruns CJ, Eichhorst ST, Gallmeier E, Kolligs FT, Göke B, De Toni EN. Mucha SR, et al. Among authors: de toni en. Gut. 2009 May;58(5):688-98. doi: 10.1136/gut.2008.154625. Epub 2008 Dec 23. Gut. 2009. PMID: 19106147

4

Amiloride reduces portal hypertension in rat liver cirrhosis.

Steib CJ, Hennenberg M, Beitinger F, Hartmann AC, Bystron M, De Toni EN, Gerbes AL. Steib CJ, et al. Among authors: de toni en. Gut. 2010 Jun;59(6):827-36. doi: 10.1136/gut.2009.197756. Gut. 2010. PMID: 20551467

5

Use of checkpoint inhibitors in liver transplant recipients.

Munker S, De Toni EN. Munker S, et al. Among authors: de toni en. United European Gastroenterol J. 2018 Aug;6(7):970-973. doi: 10.1177/2050640618774631. Epub 2018 Apr 30. United European Gastroenterol J. 2018. PMID: 30228883 Free PMC article. Review.

6

Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study.

De Toni EN, Schlesinger-Raab A, Fuchs M, Schepp W, Ehmer U, Geisler F, Ricke J, Paprottka P, Friess H, Werner J, Gerbes AL, Mayerle J, Engel J. De Toni EN, et al. Gut. 2020 Jan;69(1):168-176. doi: 10.1136/gutjnl-2018-318193. Epub 2019 Mar 16. Gut. 2020. PMID: 30878947 Free PMC article.

7

Checkpoint Inhibitors.

Heinzerling L, de Toni EN, Schett G, Hundorfean G, Zimmer L. Heinzerling L, et al. Among authors: de toni en. Dtsch Arztebl Int. 2019 Feb 22;116(8):119-126. doi: 10.3238/arztebl.2019.0119. Dtsch Arztebl Int. 2019. PMID: 30940340 Free PMC article. Review.

8

Using dual checkpoint blockade to treat fibrolamellar hepatocellular carcinoma.

De Toni EN, Roessler D. De Toni EN, et al. Gut. 2020 Nov;69(11):2056-2058. doi: 10.1136/gutjnl-2020-320604. Epub 2020 Feb 12. Gut. 2020. PMID: 32051207 No abstract available.

9

Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells.

Reiter FP, Denk G, Ziesch A, Ofner A, Wimmer R, Hohenester S, Schiergens TS, Spampatti M, Ye L, Itzel T, Munker S, Teufel A, Gerbes AL, Mayerle J, De Toni EN. Reiter FP, et al. Among authors: de toni en. Cell Oncol (Dordr). 2019 Oct;42(5):705-715. doi: 10.1007/s13402-019-00458-8. Epub 2019 Jun 27. Cell Oncol (Dordr). 2019. PMID: 31250364

10

The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma.

Ye L, Mayerle J, Ziesch A, Reiter FP, Gerbes AL, De Toni EN. Ye L, et al. Among authors: de toni en. Cell Death Discov. 2019 Apr 5;5:86. doi: 10.1038/s41420-019-0165-7. eCollection 2019. Cell Death Discov. 2019. PMID: 30962952 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results